AbbVie receives FDA CRL for trenibotulinumtoxinE, citing manufacturing information requests with no safety or efficacy concerns.
Written By: Samiksha Jadhav BPharm
Reviewed By: Pharmacally Editorial Team
AbbVie has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding its Biologics License Application for trenibotulinumtoxinE (TrenibotE), an investigational botulinum toxin type E for aesthetic use.
The FDA has requested additional information related to manufacturing processes, but did not raise any concerns about the product’s safety or efficacy or request further clinical studies. AbbVie stated it plans to address the agency’s comments and resubmit its application in the coming months.
TrenibotulinumtoxinE is a first-in-class botulinum neurotoxin serotype E designed to provide a rapid onset of action, with effects observed as early as 8 hours, and a shorter duration of effect of approximately two to three weeks.
Its clinical development program included more than 2,100 patients across two pivotal Phase 3 studies for moderate to severe glabellar lines and a Phase 3 open-label safety study, supporting its safety and efficacy profile.
In a company statement, Chief Scientific Officer Roopal Thakkar indicated that while the outcome is disappointing, AbbVie remains confident in the strength of its application and the potential of TrenibotE as an innovation in botulinum toxin science for facial aesthetics, and expects to respond promptly to the FDA’s feedback.
Regulatory reviews for the product are also ongoing in other countries and are progressing as expected. TrenibotulinumtoxinE is being developed under Allergan Aesthetics, AbbVie’s aesthetics division.
Reference
About the Writer
Samiksha Vikram Jadhav is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.